CCHT
CCHT has formed the development platform for three industries including ge
Changchun High-tech Industry, founded in 1993 and was listed at Shenzhen Stock Exchange in 1996. It has established its industrial orientation with the biopharmaceutical industry as the primary and real estate industry as the supplement, has formed the development platform for three industries including genetic engineering pharmaceuticals, biological vaccines and modern traditional Chinese medicine. The main shareholders are Changchun Gaoxin Chaoda Investment Company, Jin Lei and Lin Dianhai. The company's direct and indirect competitors include Yongan Pharmaceutical, Da An Gene and Beijing Genomics Institute.
The official results of the French parliamentary elections were announced, and the ruling party coalition held a relatively large number of seats
Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying
The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?
Feb 21, 2022 02:30 PM
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Yesterday 01:25 PM
Haier Biomedical 'Smart Blood City Network' Lands in Brazil
Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.
Apr 15, 2024 03:45 PM
D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline
EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.
Apr 12, 2024 06:05 PM
Changchun hi tech: nine directors, supervisors and senior management personnel increased their holdings of 84700 shares in the company
Consumer electronics stocks continued to decline